Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 11:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 7,072 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Neoplasm Clear all
Completed Phase 1Phase 2 Interventional

Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer

NCT00006225
View directory record Official record
Conditions
Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic/Myeloproliferative Diseases
Interventions
filgrastim, recombinant flt3 ligand, recombinant human thrombopoietin, recombinant interleukin-3, in vitro-treated peripheral blood stem cell transplantation
Biological · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 24, 2026, 11:12 AM EDT
Terminated Phase 2 Interventional

Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer

NCT00045591
View directory record Official record
Conditions
Breast Cancer
Interventions
Celecoxib
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
74
States / cities
Anniston, Alabama • La Jolla, California • Los Angeles, California + 55 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 24, 2026, 11:12 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Real-time Intraoperative Breast Cancer Visualization for Margin Assessment

NCT02807597
View directory record Official record
Conditions
Breast Cancer, Cancer of the Breast
Interventions
LS301, Cancer Vision Goggles and standard fluorescence imaging systems, Surgery
Drug · Device · Procedure
Lead sponsor
Samuel Achilefu
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 24, 2026, 11:12 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer

NCT03939897
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma, Recurrent Breast Carcinoma
Interventions
Abemaciclib, Biopsy Procedure, Biospecimen Collection, Copanlisib Hydrochloride, Diagnostic Imaging Testing, Echocardiography Test, Fulvestrant, Multigated Acquisition Scan
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
14
States / cities
Birmingham, Alabama • Costa Mesa, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 24, 2026, 11:12 AM EDT
Active, not recruiting Not applicable Interventional

Nature Sounds as a Pain and Anxiety Reducing Strategy in Patients Undergoing Breast Core Biopsy

NCT03238976
View directory record Official record
Conditions
Breast Cancer
Interventions
Nature sounds
Other
Lead sponsor
University of Chicago
Other
Eligibility
21 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 24, 2026, 11:12 AM EDT
Terminated Phase 1Phase 2 Interventional

GEN1047 for Solid Tumors - First in Human (FIH) Trial

NCT05180474
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms, Endometrial Cancer, Endometrial Neoplasm, Ovarian Cancer, Ovarian Neoplasms, Squamous Non Small Cell Lung Cancer (NSCLC-SCC)
Interventions
GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells.
Biological
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
6
States / cities
Los Angeles, California • New Haven, Connecticut • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 24, 2026, 11:12 AM EDT
Recruiting Phase 2 Interventional

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

NCT06318897
View directory record Official record
Conditions
Stage 1 cT1b-T1cN0M0, Triple Negative Breast Cancer
Interventions
Carboplatin, Paclitaxel, Pembrolizumab, Doxorubicin, Cyclophosphamide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 24, 2026, 11:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

KanSurvive: Testing a Model for Improving Cancer Survivorship Care in Rural Practice

NCT04763824
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
Interventions
KanSurvive ECHO and Practice Facilitation
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 24, 2026, 11:12 AM EDT
Completed Phase 3 Interventional

Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

NCT00044291
View directory record Official record
Conditions
Breast Neoplasms, Neoplasms, Hormone-dependent
Interventions
atamestane, toremifene, letrozole, aromatase inhibition, hormone therapy, endocrine therapy, antiestrogen therapy
Drug · Procedure
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
865 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
17
States / cities
Lake Havasu City, Arizona • Tucson, Arizona • Greenbrae, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2015 · Synced Oct 24, 2026, 11:12 AM EDT
Recruiting Phase 2 Interventional

5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss

NCT07044310
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Hormone Receptor-Positive Breast Carcinoma
Interventions
Biospecimen Collection, Bone Mineral Density Test, Questionnaire Administration, WBF-038
Procedure · Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 24, 2026, 11:12 AM EDT
Not listed Not applicable Interventional

Weight Gain Prevention for Breast Cancer Survivors

NCT00533338
View directory record Official record
Conditions
Breast Cancer
Interventions
Weight Gain Prevention Program, Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 24, 2026, 11:12 AM EDT
Withdrawn Not applicable Interventional

Feasibility Study of Cavity Radiofrequency Ablation in ex Vivo Mastectomy Breast Tissue

NCT02525913
View directory record Official record
Conditions
Breast Cancer
Interventions
RFA Applicator
Device
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 24, 2026, 11:12 AM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Understanding Patient Experience and Preferences for the QT Scanner Compared to Mammography

NCT04057391
View directory record Official record
Conditions
Breast Cancer Screening
Interventions
QT Scanner
Diagnostic Test
Lead sponsor
QT Ultrasound LLC
Industry
Eligibility
Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Oct 24, 2026, 11:12 AM EDT
Completed Phase 2 Interventional Results available

Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer

NCT00201760
View directory record Official record
Conditions
Breast Cancer
Interventions
Gemcitabine, Trastuzumab, Cisplatin
Drug
Lead sponsor
Kari Kendra
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Oct 24, 2026, 11:12 AM EDT
Terminated Phase 1 Interventional

Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer

NCT00937482
View directory record Official record
Conditions
Male Breast Cancer, Stage IV Breast Cancer, Stage IV Melanoma, Stage IV Non-small Cell Lung Cancer, Stage IV Renal Cell Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer, Tumors Metastatic to Brain
Interventions
cediranib maleate, whole-brain radiation therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2013 · Synced Oct 24, 2026, 11:12 AM EDT
Completed No phase listed Observational Results available

ARFI, VisR and DDAI Ultrasound for Improving Discrimination of Malignant and Unresponsive Breast Cancer

NCT03785782
View directory record Official record
Conditions
Breast Cancer
Interventions
Ultrasound
Device
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
30 Years to 90 Years · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Oct 24, 2026, 11:12 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Development of a Clinical Trial Specific Question Prompt List

NCT00662324
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Prostate Cancer
Interventions
focus groups
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 24, 2026, 11:12 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Molecular Analysis of Breast Cancer

NCT00569049
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Non-invasive Breast Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Interventions
breast tissue, lymph node tissue or blood
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
788 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 24, 2026, 11:12 AM EDT
Completed Not applicable Interventional

Sentinel Lymph Node Biopsy and Primary Tumor Gene Expression Profiling in Finding Axillary Lymph Node Metastases in Women Who Have Received Neoadjuvant Therapy for Stage II, Stage III, or Stage IV Breast Cancer

NCT00080860
View directory record Official record
Conditions
Breast Cancer
Interventions
microarray analysis, immunohistochemistry staining method, conventional surgery, lymphangiography, radionuclide imaging, sentinel lymph node biopsy, technetium Tc 99m sulfur colloid
Genetic · Other · Procedure + 1 more
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Oct 24, 2026, 11:12 AM EDT
Completed No phase listed Observational

A Comparison of Primary Care and Traditional Internal Medicine Residents

NCT00224224
View directory record Official record
Conditions
Breast Cancer Screening, Cervical Cancer Screening, Cholesterol Screening, Asthma Admission Rate, Diabetes Management
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2008 · Synced Oct 24, 2026, 11:12 AM EDT
Completed Not applicable Interventional

Yoga for Aromatase Inhibitor-associated Joint Pain

NCT01951976
View directory record Official record
Conditions
Breast Cancer
Interventions
Questionnaires, Yoga Classes
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 4, 2016 · Synced Oct 24, 2026, 11:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Engaging Diverse Underserved Communities to Bridge the Mammography Divide

NCT01267110
View directory record Official record
Conditions
Breast Cancer Screening
Interventions
MI2 intervention arm, Control
Other
Lead sponsor
University of Kansas
Other
Eligibility
40 Years and older · Female only
Enrollment
261 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2015 · Synced Oct 24, 2026, 11:12 AM EDT
Completed Early Phase 1 Interventional Results available

Proof of Principle Trial to Determine if Nutritional Supplement Conjugated Linoleic Acid (CLA) Can Modulate the Lipogenic Pathway in Breast Cancer Tissue

NCT00908791
View directory record Official record
Conditions
Breast Cancer
Interventions
Conjugated Linoleic Acid (CLA)
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Oct 24, 2026, 11:12 AM EDT
Completed Phase 3 Interventional Results available

A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer

NCT03337724
View directory record Official record
Conditions
Breast Cancer
Interventions
Ipatasertib, Paclitaxel, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
28
States / cities
La Jolla, California • Los Angeles, California • Newport Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 24, 2026, 11:12 AM EDT